Aspects on pathophysiological mechanisms in COPD

Journal of Internal Medicine

Volumn 262, Issue 3, 2007, Pages 311-340

  Larsson, Kjell ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Chemokines; COPD; Cytokines; Emphysema inflammation; Review

Indexed keywords

ACETYLCHOLINE; ACETYLCYSTEINE; AMFEBUTAMONE; ARACHIDONIC ACID DERIVATIVE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CARBON MONOXIDE; CHEMOATTRACTANT; CHEMOKINE; CYTOKINE; ENZYME; ETANERCEPT; GLUCOCORTICOID; GROWTH FACTOR; MATRIX METALLOPROTEINASE; NICOTINE; NITRIC OXIDE; PROTEINASE; PROTEINASE INHIBITOR; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; RETINOIC ACID; TIOTROPIUM BROMIDE; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; VARENICLINE;

AIRWAY OBSTRUCTION; BRONCHIOLITIS; BRONCHOSPASM; CAUSE OF DEATH; CHOLINERGIC SYSTEM; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; DISEASE EXACERBATION; DRUG TARGETING; ENVIRONMENTAL EXPOSURE; EPITHELIUM CELL; EXERCISE; FORCED EXPIRATORY VOLUME; GOBLET CELL; HUMAN; LUNG ALVEOLUS; LUNG ALVEOLUS MACROPHAGE; LUNG EMPHYSEMA; LUNG FIBROSIS; LUNG FUNCTION; LUNG INFILTRATE; LYMPHOCYTE; MACROPHAGE; MORTALITY; MUCUS SECRETION; NEUTROPHIL; NICOTINE REPLACEMENT THERAPY; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PULMONARY HYPERTENSION; RESPIRATORY EPITHELIUM; RESPIRATORY SYSTEM; RESPIRATORY TRACT INFLAMMATION; REVIEW; SMOKING; SMOKING CESSATION; TOBACCO DEPENDENCE; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

BRONCHIOLITIS; CYTOKINES; EMPHYSEMA; HUMANS; LUNG; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING;

EID: 34547851168     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2007.01837.x     Document Type: Review

References (331)

1. Mitchell RS, Filley GF. Chronic obstructive bronchopulmonary disease. I. Clinical features. Am Rev Respir Dis 1964 89: 360 71.
2. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. Am J Respir Crit Care Med 1995 152: S77 121.
3. BTS Guidelines for the Management of Chronic Obstructive Pulmonary Disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS. Thorax 1997 52 (Suppl. 5 S1 28.
4. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001 163: 1256 76.
5. Siafakas NM, Vermeire P, Pride NB et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J 1995 8: 1398 420.
6. Fletcher C, Peto R, Tinker R, Speizer FE. The Natural History of Chronic Bronchitis and Emphysema. Oxford: Oxford University Press, 1976.
7. Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996 153: 1530 5.
8. Boschetto P, Quintavalle S, Miotto D, Lo Cascio N, Zeni E, Mapp CE. Chronic obstructive pulmonary disease (COPD) and occupational exposures. J Occup Med Toxicol 2006 1: 11.
9. Oxman AD, Muir DC, Shannon HS, Stock SR, Hnizdo E, Lange HJ. Occupational dust exposure and chronic obstructive pulmonary disease. A systematic overview of the evidence. Am Rev Respir Dis 1993 148: 38 48.
10. Lundback B, Lindberg A, Lindstrom M et al. Not 15 but 50% of smokers develop COPD? Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med 2003 97: 115 22.
11. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004 23: 932 46.
12. GOLD 2004) Global Strategy for Diagnosis, Management, and Prevention of COPD. http://www.goldcopd.com. [accessed on 24 May 2007].
13. Clark KD, Wardrobe-Wong N, Elliott JJ, Gill PT, Tait NP, Snashall PD. Patterns of lung disease in a "normal" smoking population: are emphysema and airflow obstruction found together? Chest 2001 120: 743 7.
14. Sashidhar K, Gulati M, Gupta D, Monga S, Suri S. Emphysema in heavy smokers with normal chest radiography. Detection and quantification by HCRT. Acta Radiol 2002 43: 60 5.
15. Tylen U, Boijsen M, Ekberg-Jansson A, Bake B, Lofdahl CG. Emphysematous lesions and lung function in healthy smokers 60 years of age. Respir Med 2000 94: 38 43.
16. Gould GA, Redpath AT, Ryan M et al. Lung CT density correlates with measurements of airflow limitation and the diffusing capacity. Eur Respir J 1991 4: 141 6.
17. Park KJ, Bergin CJ, Clausen JL. Quantitation of emphysema with three-dimensional CT densitometry: comparison with two-dimensional analysis, visual emphysema scores, and pulmonary function test results. Radiology 1999 211: 541 7.
18. Fain SB, Panth SR, Evans MD et al. Early emphysematous changes in asymptomatic smokers: detection with 3He MR imaging. Radiology 2006 239: 875 83.
19. Coxson HO, Rogers RM, Whittall KP et al. A quantification of the lung surface area in emphysema using computed tomography. Am J Respir Crit Care Med 1999 159: 851 6.
20. Gugger M, Gould G, Sudlow MF, Wraith PK, MacNee W. Extent of pulmonary emphysema in man and its relation to the loss of elastic recoil. Clin Sci (Lond) 1991 80: 353 8.
21. Anto JM, Vermeire P, Vestbo J, Sunyer J. Epidemiology of chronic obstructive pulmonary disease. Eur Respir J 2001 17: 982 94.
22. Rijken B, Britton J. Epidemiology of chronic obstructive pulmonary disease. In: Postma D, Siafakas N, eds. Management of Chronic Obstructive Pulmonary Disease. Sheffield: European Respiratory Society 1998 7: 41 73.
23. Anthonisen NR, Wright EC, Hodgkin JE. Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986 133: 14 20.
24. Donaldson GC, Seemungal TA, Patel IS et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest 2005 128: 1995 2004.
25. Gallagher CG, Brown E, Younes M. Breathing pattern during maximal exercise and during submaximal exercise with hypercapnia. J Appl Physiol 1987 63: 238 44.
26. Younes M, Kivinen G. Respiratory mechanics and breathing pattern during and following maximal exercise. J Appl Physiol 1984 57: 1773 82.
27. O'Donnell DE, Bertley JC, Chau LK, Webb KA. Qualitative aspects of exertional breathlessness in chronic airflow limitation: pathophysiologic mechanisms. Am J Respir Crit Care Med 1997 155: 109 15.
28. O'Donnell DE, Webb KA. Exertional breathlessness in patients with chronic airflow limitation. The role of lung hyperinflation. Am Rev Respir Dis 1993 148: 1351 7.
29. Graydon JE, Ross E, Webster PM, Goldstein RS, Avendano M. Predictors of functioning of patients with chronic obstructive pulmonary disease. Heart Lung 1995 24: 369 75.
30. Jones PW. Issues concerning health-related quality of life in COPD. Chest 1995 107: 187S 93S.
31. Ketelaars CA, Schlosser MA, Mostert R, Huyer Abu-Saad H, Halfens RJ, Wouters EF. Determinants of health-related quality of life in patients with chronic obstructive pulmonary disease. Thorax 1996 51: 39 43.
32. Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002 121: 1434 40.
33. Belman MJ, Botnick WC, Shin JW. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996 153: 967 75.
34. Casanova C, Cote C, de Torres JP et al. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005 171: 591 7.
35. O'Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001 164: 770 7.
36. O'Donnell DE, Webb KA. Breathlessness in patients with severe chronic airflow limitation. Physiologic correlations. Chest 1992 102: 824 31.
37. O'Donnell DE, Fluge T, Gerken F et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004 23: 832 40.
38. O'Donnell DE, Voduc N, Fitzpatrick M, Webb KA. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J 2004 24: 86 94.
39. Niewoehner DE, Kleinerman J, Rice DB. Pathologic changes in the peripheral airways of young cigarette smokers. N Engl J Med 1974 291: 755 8.
40. Hogg JC, Macklem PT, Thurlbeck WM. Site and nature of airway obstruction in chronic obstructive lung disease. N Engl J Med 1968 278: 1355 60.
41. Hogg JC, Wright JL, Wiggs BR, Coxson HO, Opazo Saez A, Pare PD. Lung structure and function in cigarette smokers. Thorax 1994 49: 473 8.
42. Cosio M, Ghezzo H, Hogg JC et al. The relations between structural changes in small airways and pulmonary-function tests. N Engl J Med 1978 298: 1277 81.
43. Saetta M, Di Stefano A, Turato G et al. CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998 157: 822 6.
44. Saetta M, Turato G, Baraldo S et al. Goblet cell hyperplasia and epithelial inflammation in peripheral airways of smokers with both symptoms of chronic bronchitis and chronic airflow limitation. Am J Respir Crit Care Med 2000 161: 1016 21.
45. Matsuba K, Thurlbeck WM. The number and dimensions of small airways in emphysematous lungs. Am J Pathol 1972 67: 265 75.
46. Yanai M, Sekizawa K, Ohrui T, Sasaki H, Takishima T. Site of airway obstruction in pulmonary disease: direct measurement of intrabronchial pressure. J Appl Physiol 1992 72: 1016 23.
47. Donnelly LE, Barnes PJ. Chemokine receptors as therapeutic targets in chronic obstructive pulmonary disease. Trends Pharmacol Sci 2006 27: 546 53.
48. Loetscher P, Clark-Lewis I. Agonistic and antagonistic activities of chemokines. J Leukoc Biol 2001 69: 881 4.
49. Moser B, Wolf M, Walz A, Loetscher P. Chemokines: multiple levels of leukocyte migration control. Trends Immunol 2004 25: 75 84.
50. Panina P, Mariani M, D'Ambrosio D. Chemokine receptors in chronic obstructive pulmonary disease (COPD). Curr Drug Targets 2006 7: 669 74.
51. Hunninghake GW, Crystal RG. Cigarette smoking and lung destruction. Accumulation of neutrophils in the lungs of cigarette smokers. Am Rev Respir Dis 1983 128: 833 8.
52. Woolhouse IS, Bayley DL, Stockley RA. Sputum chemotactic activity in chronic obstructive pulmonary disease: effect of alpha(1)-antitrypsin deficiency and the role of leukotriene B(4) and interleukin 8. Thorax 2002 57: 709 14.
53. Butcher EC. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell 1991 67: 1033 6.
54. Di Stefano A, Capelli A, Lusuardi M et al. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med 1998 158: 1277 85.
55. O'Donnell RA, Peebles C, Ward JA et al. Relationship between peripheral airway dysfunction, airway obstruction, and neutrophilic inflammation in COPD. Thorax 2004 59: 837 42.
56. Stanescu D, Sanna A, Veriter C et al. Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils. Thorax 1996 51: 267 71.
57. Saetta M, Turato G, Facchini FM et al. Inflammatory cells in the bronchial glands of smokers with chronic bronchitis. Am J Respir Crit Care Med 1997 156: 1633 9.
58. Gillum RF. Peripheral leukocyte count and pulmonary function in a national sample of women and men. Ann Epidemiol 1991 1: 525 31.
59. Sparrow D, Glynn RJ, Cohen M, Weiss ST. The relationship of the peripheral leukocyte count and cigarette smoking to pulmonary function among adult men. Chest 1984 86: 383 6.
60. Beeh KM, Kornmann O, Buhl R, Culpitt SV, Giembycz MA, Barnes PJ. Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4. Chest 2003 123: 1240 7.
61. Tanino M, Betsuyaku T, Takeyabu K et al. Increased levels of interleukin-8 in BAL fluid from smokers susceptible to pulmonary emphysema. Thorax 2002 57: 405 11.
62. Traves SL, Culpitt SV, Russell RE, Barnes PJ, Donnelly LE. Increased levels of the chemokines GROalpha and MCP-1 in sputum samples from patients with COPD. Thorax 2002 57: 590 5.
63. Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996 153: 530 4.
64. Perng DW, Huang HY, Chen HM, Lee YC, Perng RP. Characteristics of airway inflammation and bronchodilator reversibility in COPD: a potential guide to treatment. Chest 2004 126: 375 81.
65. Yamamoto C, Yoneda T, Yoshikawa M et al. Airway inflammation in COPD assessed by sputum levels of interleukin-8. Chest 1997 112: 505 10.
66. Hill AT, Campbell EJ, Hill SL, Bayley DL, Stockley RA. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med 2000 109: 288 95.
67. Crooks SW, Bayley DL, Hill SL, Stockley RA. Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis: the role of leukotriene B4. Eur Respir J 2000 15: 274 80.
68. Gompertz S, O'Brien C, Bayley DL, Hill SL, Stockley RA. Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. Eur Respir J 2001 17: 1112 9.
69. Lee CG, Homer RJ, Zhu Z et al. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J Exp Med 2001 194: 809 21.
70. Lee E, Lindo T, Jackson N et al. Reversal of human neutrophil survival by leukotriene B(4) receptor blockade and 5-lipoxygenase and 5-lipoxygenase activating protein inhibitors. Am J Respir Crit Care Med 1999 160: 2079 85.
71. Baggiolini M, Dewald B, Moser B. Interleukin-8 and related chemotactic cytokines - CXC and CC chemokines. Adv Immunol 1994 55: 97 179.
72. Clark-Lewis I, Kim KS, Rajarathnam K et al. Structure-activity relationships of chemokines. J Leukoc Biol 1995 57: 703 11.
73. Qiu Y, Zhu J, Bandi V et al. Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003 168: 968 75.
74. De Boer WI, Sont JK, Van Schadewijk A, Stolk J, Van Krieken JH, Hiemstra PS. Monocyte chemoattractant protein 1, interleukin 8, and chronic airways inflammation in COPD. J Pathol 2000 190: 619 26.
75. Profita M, Chiappara G, Mirabella F et al. Effect of cilomilast (Ariflo) on TNF-alpha, IL-8, and GM-CSF release by airway cells of patients with COPD. Thorax 2003 58: 573 9.
76. Yoshikawa T, Dent G, Ward J et al. Impaired neutrophil chemotaxis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007 175: 473 9.
77. Drost EM, MacNee W. Potential role of IL-8, platelet-activating factor and TNF-alpha in the sequestration of neutrophils in the lung: effects on neutrophil deformability, adhesion receptor expression, and chemotaxis. Eur J Immunol 2002 32: 393 403.
78. Noguera A, Batle S, Miralles C et al. Enhanced neutrophil response in chronic obstructive pulmonary disease. Thorax 2001 56: 432 7.
79. Maestrelli P, Calcagni PG, Saetta M et al. Integrin upregulation on sputum neutrophils in smokers with chronic airway obstruction. Am J Respir Crit Care Med 1996 154: 1296 300.
80. Klein CL, Bittinger F, Kohler H et al. Comparative studies on vascular endothelium in vitro. 3. Effects of cytokines on the expression of E-selectin, ICAM-1 and VCAM-1 by cultured human endothelial cells obtained from different passages. Pathobiology 1995 63: 83 92.
81. Scholz D, Devaux B, Hirche A et al. Expression of adhesion molecules is specific and time-dependent in cytokine-stimulated endothelial cells in culture. Cell Tissue Res 1996 284: 415 23.
82. Riise GC, Larsson S, Lofdahl CG, Andersson BA. Circulating cell adhesion molecules in bronchial lavage and serum in COPD patients with chronic bronchitis. Eur Respir J 1994 7: 1673 7.
83. Noguera A, Busquets X, Sauleda J, Villaverde JM, MacNee W, Agusti AG. Expression of adhesion molecules and G proteins in circulating neutrophils in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998 158: 1664 8.
84. O'Shaughnessy TC, Ansari TW, Barnes NC, Jeffery PK. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1. Am J Respir Crit Care Med 1997 155: 852 7.
85. Thompson AB, Daughton D, Robbins RA, Ghafouri MA, Oehlerking M, Rennard SI. Intraluminal airway inflammation in chronic bronchitis. Characterization and correlation with clinical parameters. Am Rev Respir Dis 1989 140: 1527 37.
86. Di Stefano A, Maestrelli P, Roggeri A et al. Upregulation of adhesion molecules in the bronchial mucosa of subjects with chronic obstructive bronchitis. Am J Respir Crit Care Med 1994 149: 803 10.
87. Hill AT, Bayley D, Stockley RA. The interrelationship of sputum inflammatory markers in patients with chronic bronchitis. Am J Respir Crit Care Med 1999 160: 893 8.
88. Drost EM, Selby C, Bridgeman MM, MacNee W. Decreased leukocyte deformability after acute cigarette smoking in humans. Am Rev Respir Dis 1993 148: 1277 83.
89. MacNee W, Wiggs B, Belzberg AS, Hogg JC. The effect of cigarette smoking on neutrophil kinetics in human lungs. N Engl J Med 1989 321: 924 8.
90. Saetta M, Di Stefano A, Maestrelli P et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 1994 150: 1646 52.
91. Keatings VM, Barnes PJ. Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma, and normal subjects. Am J Respir Crit Care Med 1997 155: 449 53.
92. Louis RE, Cataldo D, Buckley MG et al. Evidence of mast-cell activation in a subset of patients with eosinophilic chronic obstructive pulmonary disease. Eur Respir J 2002 20: 325 31.
93. Zhu J, Qiu YS, Majumdar S et al. Exacerbations of bronchitis: bronchial eosinophilia and gene expression for interleukin-4, interleukin-5, and eosinophil chemoattractants. Am J Respir Crit Care Med 2001 164: 109 16.
94. Fujimoto K, Yasuo M, Urushibata K, Hanaoka M, Koizumi T, Kubo K. Airway inflammation during stable and acutely exacerbated chronic obstructive pulmonary disease. Eur Respir J 2005 25: 640 6.
95. Saetta M, Di Stefano A, Maestrelli P et al. Airway eosinophilia and expression of interleukin-5 protein in asthma and in exacerbations of chronic bronchitis. Clin Exp Allergy 1996 26: 766 74.
96. Bocchino V, Bertorelli G, Bertrand CP et al. Eotaxin and CCR3 are up-regulated in exacerbations of chronic bronchitis. Allergy 2002 57: 17 22.
97. Ravensberg AJ, Ricciardolo FL, van Schadewijk A et al. Eotaxin-2 and eotaxin-3 expression is associated with persistent eosinophilic bronchial inflammation in patients with asthma after allergen challenge. J Allergy Clin Immunol 2005 115: 779 85.
98. Vachier I, Vignola AM, Chiappara G et al. Inflammatory features of nasal mucosa in smokers with and without COPD. Thorax 2004 59: 303 7.
99. Brightling CE, McKenna S, Hargadon B et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax 2005 60: 193 8.
100. Chanez P, Vignola AM, O'Shaugnessy T et al. Corticosteroid reversibility in COPD is related to features of asthma. Am J Respir Crit Care Med 1997 155: 1529 34.
101. Leigh R, Pizzichini MM, Morris MM, Maltais F, Hargreave FE, Pizzichini E. Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J 2006 27: 964 71.
102. Fathi M, Johansson A, Lundborg M, Orre L, Skold CM, Camner P. Functional and morphological differences between human alveolar and interstitial macrophages. Exp Mol Pathol 2001 70: 77 82.
103. Laskin DL, Weinberger B, Laskin JD. Functional heterogeneity in liver and lung macrophages. J Leukoc Biol 2001 70: 163 70.
104. Retamales I, Elliott WM, Meshi B et al. Amplification of inflammation in emphysema and its association with latent adenoviral infection. Am J Respir Crit Care Med 2001 164: 469 73.
105. Finkelstein R, Fraser RS, Ghezzo H, Cosio MG. Alveolar inflammation and its relation to emphysema in smokers. Am J Respir Crit Care Med 1995 152: 1666 72.
106. Koyama S, Rennard SI, Daughton D, Shoji S, Robbins RA. Bronchoalveolar lavage fluid obtained from smokers exhibits increased monocyte chemokinetic activity. J Appl Physiol 1991 70: 1208 14.
107. Schrum S, Probst P, Fleischer B, Zipfel PF. Synthesis of the CC-chemokines MIP-1alpha, MIP-1beta, and RANTES is associated with a type 1 immune response. J Immunol 1996 157: 3598 604.
108. Becker S, Quay J, Koren HS, Haskill JS. Constitutive and stimulated MCP-1, GRO alpha, beta, and gamma expression in human airway epithelium and bronchoalveolar macrophages. Am J Physiol 1994 266: L278 86.
109. Capelli A, Di Stefano A, Gnemmi I et al. Increased MCP-1 and MIP-1beta in bronchoalveolar lavage fluid of chronic bronchitics. Eur Respir J 1999 14: 160 5.
110. Gerszten RE, Garcia-Zepeda EA, Lim YC et al. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 1999 398: 718 23.
111. Huo Y, Weber C, Forlow SB et al. The chemokine KC, but not monocyte chemoattractant protein-1, triggers monocyte arrest on early atherosclerotic endothelium. J Clin Invest 2001 108: 1307 14.
112. Traves SL, Smith SJ, Barnes PJ, Donnelly LE. Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: a role for CXCR2. J Leukoc Biol 2004 76: 441 50.
113. Culpitt SV, Rogers DF, Shah P et al. Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003 167: 24 31.
114. Takanashi S, Hasegawa Y, Kanehira Y et al. Interleukin-10 level in sputum is reduced in bronchial asthma, COPD and in smokers. Eur Respir J 1999 14: 309 14.
115. Lim S, Roche N, Oliver BG, Mattos W, Barnes PJ, Chung KF. Balance of matrix metalloprotease-9 and tissue inhibitor of metalloprotease-1 from alveolar macrophages in cigarette smokers. Regulation by interleukin-10. Am J Respir Crit Care Med 2000 162: 1355 60.
116. Fabbri LM, Romagnoli M, Corbetta L et al. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003 167: 418 24.
117. Peinado VI, Barbera JA, Abate P et al. Inflammatory reaction in pulmonary muscular arteries of patients with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999 159: 1605 11.
118. Saetta M, Baraldo S, Turato G et al. Increased proportion of CD8+ T-lymphocytes in the paratracheal lymph nodes of smokers with mild COPD. Sarcoidosis Vasc Diffuse Lung Dis 2003 20: 28 32.
119. Kim WD, Kim WS, Koh Y et al. Abnormal peripheral blood T-lymphocyte subsets in a subgroup of patients with COPD. Chest 2002 122: 437 44.
120. Saetta M, Baraldo S, Corbino L et al. CD8+ve cells in the lungs of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999 160: 711 7.
121. Grumelli S, Corry DB, Song LZ et al. An immune basis for lung parenchymal destruction in chronic obstructive pulmonary disease and emphysema. PLoS Med 2004 1: e8.
122. Sallusto F, Kremmer E, Palermo B et al. Switch in chemokine receptor expression upon TCR stimulation reveals novel homing potential for recently activated T cells. Eur J Immunol 1999 29: 2037 45.
123. Sallusto F, Lenig D, Mackay CR, Lanzavecchia A. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med 1998 187: 875 83.
124. Farber JM. Mig and IP-10: CXC chemokines that target lymphocytes. J Leukoc Biol 1997 61: 246 57.
125. Saetta M, Mariani M, Panina-Bordignon P et al. Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002 165: 1404 9.
126. Hardaker EL, Bacon AM, Carlson K et al. Regulation of TNF-alpha- and IFN-gamma-induced CXCL10 expression: participation of the airway smooth muscle in the pulmonary inflammatory response in chronic obstructive pulmonary disease. FASEB J 2004 18: 191 3.
127. Loetscher P, Pellegrino A, Gong JH et al. The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3. J Biol Chem 2001 276: 2986 91.
128. Ogilvie P, Bardi G, Clark-Lewis I, Baggiolini M, Uguccioni M. Eotaxin is a natural antagonist for CCR2 and an agonist for CCR5. Blood 2001 97: 1920 4.
129. Jeffery PK. Comparison of the structural and inflammatory features of COPD and asthma. Giles F. Filley Lecture. Chest 2000 117: 251S 60S.
130. Mio T, Romberger DJ, Thompson AB, Robbins RA, Heires A, Rennard SI. Cigarette smoke induces interleukin-8 release from human bronchial epithelial cells. Am J Respir Crit Care Med 1997 155: 1770 6.
131. Ek A, Larsson K, Siljerud S, Palmberg L. Fluticasone and budesonide inhibit cytokine release in human lung epithelial cells and alveolar macrophages. Allergy 1999 54: 691 9.
132. Liden J, Ek A, Palmberg L, Okret S, Larsson K. Organic dust activates NF-kappaB in lung epithelial cells. Respir Med 2003 97: 882 92.
133. Palmberg L, Larsson BM, Malmberg P, Larsson K. Induction of IL-8 production in human alveolar macrophages and human bronchial epithelial cells in vitro by swine dust. Thorax 1998 53: 260 4.
134. Standiford TJ, Kunkel SL, Basha MA et al. Interleukin-8 gene expression by a pulmonary epithelial cell line. A model for cytokine networks in the lung. J Clin Invest 1990 86: 1945 53.
135. Striz I, Mio T, Adachi Y, Robbins RA, Romberger DJ, Rennard SI. IL-4 and IL-13 stimulate human bronchial epithelial cells to release IL-8. Inflammation 1999 23: 545 55.
136. Aarvak T, Chabaud M, Miossec P, Natvig JB. IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. J Immunol 1999 162: 1246 51.
137. Shin HC, Benbernou N, Esnault S, Guenounou M. Expression of IL-17 in human memory CD45RO+ T lymphocytes and its regulation by protein kinase A pathway. Cytokine 1999 11: 257 66.
138. Kawaguchi M, Kokubu F, Matsukura S et al. Induction of C-X-C chemokines, growth-related oncogene alpha expression, and epithelial cell-derived neutrophil-activating protein-78 by ML-1 (interleukin-17 F) involves activation of Raf1-mitogen-activated protein kinase kinase-extracellular signal-regulated kinase 1/2 pathway. J Pharmacol Exp Ther 2003 307: 1213 20.
139. Prause O, Laan M, Lotvall J, Linden A. Pharmacological modulation of interleukin-17-induced GCP-2-, GRO-alpha- and interleukin-8 release in human bronchial epithelial cells. Eur J Pharmacol 2003 462: 193 8.
140. Wang JH, Devalia JL, Xia C, Sapsford RJ, Davies RJ. Expression of RANTES by human bronchial epithelial cells in vitro and in vivo and the effect of corticosteroids. Am J Respir Cell Mol Biol 1996 14: 27 35.
141. Tosi MF, Stark JM, Smith CW, Hamedani A, Gruenert DC, Infeld MD. Induction of ICAM-1 expression on human airway epithelial cells by inflammatory cytokines: effects on neutrophil-epithelial cell adhesion. Am J Respir Cell Mol Biol 1992 7: 214 21.
142. Albelda SM. Endothelial and epithelial cell adhesion molecules. Am J Respir Cell Mol Biol 1991 4: 195 203.
143. Floreani AA, Wyatt TA, Stoner J et al. Smoke and C5a induce airway epithelial intercellular adhesion molecule-1 and cell adhesion. Am J Respir Cell Mol Biol 2003 29: 472 82.
144. Pelton RW, Johnson MD, Perkett EA, Gold LI, Moses HL. Expression of transforming growth factor-beta 1, -beta 2, and -beta 3 mRNA and protein in the murine lung. Am J Respir Cell Mol Biol 1991 5: 522 30.
145. Sacco O, Romberger D, Rizzino A, Beckmann JD, Rennard SI, Spurzem JR. Spontaneous production of transforming growth factor-beta 2 by primary cultures of bronchial epithelial cells. Effects on cell behavior in vitro. J Clin Invest 1992 90: 1379 85.
146. Steigerwalt RW, Rundhaug JE, Nettesheim P. Transformed rat tracheal epithelial cells exhibit alterations in transforming growth factor-beta secretion and responsiveness. Mol Carcinog 1992 5: 32 40.
147. Thompson HG, Mih JD, Krasieva TB, Tromberg BJ, George SC. Epithelial-derived TGF-beta2 modulates basal and wound-healing subepithelial matrix homeostasis. Am J Physiol Lung Cell Mol Physiol 2006 291: L1277 85.
148. Ishikawa T, Kume H, Kondo M, Ito Y, Yamaki K, Shimokata K. Inhibitory effects of interferon-gamma on the heterologous desensitization of beta-adrenoceptors by transforming growth factor-beta 1 in tracheal smooth muscle. Clin Exp Allergy 2003 33: 808 15.
149. Mak JC, Rousell J, Haddad EB, Barnes PJ. Transforming growth factor-beta1 inhibits beta2-adrenoceptor gene transcription. Naunyn Schmiedebergs Arch Pharmacol 2000 362: 520 5.
150. Shao MX, Nakanaga T, Nadel JA. Cigarette smoke induces MUC5AC mucin overproduction via tumor necrosis factor-alpha-converting enzyme in human airway epithelial (NCI-H292) cells. Am J Physiol Lung Cell Mol Physiol 2004 287: L420 7.
151. Takeyama K, Jung B, Shim JJ et al. Activation of epidermal growth factor receptors is responsible for mucin synthesis induced by cigarette smoke. Am J Physiol Lung Cell Mol Physiol 2001 280: L165 72.
152. Li JD, Feng W, Gallup M et al. Activation of NF-kappaB via a Src-dependent Ras-MAPK-pp90rsk pathway is required for Pseudomonas aeruginosa-induced mucin overproduction in epithelial cells. Proc Natl Acad Sci U S A 1998 95: 5718 23.
153. Shao MX, Ueki IF, Nadel JA. Tumor necrosis factor alpha-converting enzyme mediates MUC5AC mucin expression in cultured human airway epithelial cells. Proc Natl Acad Sci U S A 2003 100: 11618 23.
154. Takeyama K, Dabbagh K, Jeong Shim J, Dao-Pick T, Ueki IF, Nadel JA. Oxidative stress causes mucin synthesis via transactivation of epidermal growth factor receptor: role of neutrophils. J Immunol 2000 164: 1546 52.
155. Perrais M, Pigny P, Copin MC, Aubert JP, Van Seuningen I. Induction of MUC2 and MUC5AC mucins by factors of the epidermal growth factor (EGF) family is mediated by EGF receptor/Ras/Raf/extracellular signal-regulated kinase cascade and Sp1. J Biol Chem 2002 277: 32258 67.
156. Song KS, Lee WJ, Chung KC et al. Interleukin-1 beta and tumor necrosis factor-alpha induce MUC5AC overexpression through a mechanism involving ERK/p38 mitogen-activated protein kinases-MSK1-CREB activation in human airway epithelial cells. J Biol Chem 2003 278: 23243 50.
157. Baginski TK, Dabbagh K, Satjawatcharaphong C, Swinney DC. Cigarette smoke synergistically enhances respiratory mucin induction by proinflammatory stimuli. Am J Respir Cell Mol Biol 2006 35: 165 74.
158. Farkas L, Hahn MC, Schmoczer M et al. Expression of CXC chemokine receptors 1 and 2 in human bronchial epithelial cells. Chest 2005 128: 3724 34.
159. Marklund SL. Human copper-containing superoxide dismutase of high molecular weight. Proc Natl Acad Sci U S A 1982 79: 7634 8.
160. Oury TD, Chang LY, Marklund SL, Day BJ, Crapo JD. Immunocytochemical localization of extracellular superoxide dismutase in human lung. Lab Invest 1994 70: 889 98.
161. Oury TD, Day BJ, Crapo JD. Extracellular superoxide dismutase: a regulator of nitric oxide bioavailability. Lab Invest 1996 75: 617 36.
162. Abboud RT, Fera T, Richter A, Tabona MZ, Johal S. Acute effect of smoking on the functional activity of alpha1-protease inhibitor in bronchoalveolar lavage fluid. Am Rev Respir Dis 1985 131: 79 85.
163. Evans MD, Pryor WA. Damage to human alpha-1-proteinase inhibitor by aqueous cigarette tar extracts and the formation of methionine sulfoxide. Chem Res Toxicol 1992 5: 654 60.
164. Janoff A, Carp H, Laurent P, Raju L. The role of oxidative processes in emphysema. Am Rev Respir Dis 1983 127: S31 8.
165. Aoshiba K, Yasuda K, Yasui S, Tamaoki J, Nagai A. Serine proteases increase oxidative stress in lung cells. Am J Physiol Lung Cell Mol Physiol 2001 281: L556 64.
166. Schaberg T, Haller H, Rau M, Kaiser D, Fassbender M, Lode H. Superoxide anion release induced by platelet-activating factor is increased in human alveolar macrophages from smokers. Eur Respir J 1992 5: 387 93.
167. Dye JA, Adler KB. Effects of cigarette smoke on epithelial cells of the respiratory tract. Thorax 1994 49: 825 34.
168. Wright DT, Fischer BM, Li C, Rochelle LG, Akley NJ, Adler KB. Oxidant stress stimulates mucin secretion and PLC in airway epithelium via a nitric oxide-dependent mechanism. Am J Physiol 1996 271: L854 61.
169. Feldman C, Anderson R, Kanthakumar K, Vargas A, Cole PJ, Wilson R. Oxidant-mediated ciliary dysfunction in human respiratory epithelium. Free Radic Biol Med 1994 17: 1 10.
170. Tuder RM, Zhen L, Cho CY et al. Oxidative stress and apoptosis interact and cause emphysema due to vascular endothelial growth factor receptor blockade. Am J Respir Cell Mol Biol 2003 29: 88 97.
171. Dekhuijzen PN, Aben KK, Dekker I et al. Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996 154: 813 6.
172. Montuschi P, Collins JV, Ciabattoni G et al. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am J Respir Crit Care Med 2000 162: 1175 7.
173. Stockley RA. Neutrophils and the pathogenesis of COPD. Chest 2002 121: 151S 5S.
174. Kuhn C, Yu SY, Chraplyvy M, Linder HE, Senior RM. The induction of emphysema with elastase. II. Changes in connective tissue. Lab Invest 1976 34: 372 80.
175. Snider GL, Lucey EC, Stone PJ. Animal models of emphysema. Am Rev Respir Dis 1986 133: 149 69.
176. Harel S, Janoff A, Yu SY, Hurewitz A, Bergofsky EH. Desmosine radioimmunoassay for measuring elastin degradation in vivo. Am Rev Respir Dis 1980 122: 769 73.
177. Gottlieb DJ, Stone PJ, Sparrow D et al. Urinary desmosine excretion in smokers with and without rapid decline of lung function: the Normative Aging Study. Am J Respir Crit Care Med 1996 154: 1290 5.
178. Walsh DE, Greene CM, Carroll TP et al. Interleukin-8 up-regulation by neutrophil elastase is mediated by MyD88/IRAK/TRAF-6 in human bronchial epithelium. J Biol Chem 2001 276: 35494 9.
179. Hubbard RC, Fells G, Gadek J, Pacholok S, Humes J, Crystal RG. Neutrophil accumulation in the lung in alpha 1-antitrypsin deficiency. Spontaneous release of leukotriene B4 by alveolar macrophages. J Clin Invest 1991 88: 891 7.
180. Suzuki T, Wang W, Lin JT, Shirato K, Mitsuhashi H, Inoue H. Aerosolized human neutrophil elastase induces airway constriction and hyperresponsiveness with protection by intravenous pretreatment with half-length secretory leukoprotease inhibitor. Am J Respir Crit Care Med 1996 153: 1405 11.
181. Voynow JA, Young LR, Wang Y, Horger T, Rose MC, Fischer BM. Neutrophil elastase increases MUC5AC mRNA and protein expression in respiratory epithelial cells. Am J Physiol 1999 276: L835 43.
182. Zheng T, Zhu Z, Wang Z et al. Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema. J Clin Invest 2000 106: 1081 93.
183. Campbell EJ, Cury JD, Shapiro SD, Goldberg GI, Welgus HG. Neutral proteinases of human mononuclear phagocytes. Cellular differentiation markedly alters cell phenotype for serine proteinases, metalloproteinases, and tissue inhibitor of metalloproteinases. J Immunol 1991 146: 1286 93.
184. Vernooy JH, Lindeman JH, Jacobs JA, Hanemaaijer R, Wouters EF. Increased activity of matrix metalloproteinase-8 and matrix metalloproteinase-9 in induced sputum from patients with COPD. Chest 2004 126: 1802 10.
185. Hautamaki RD, Kobayashi DK, Senior RM, Shapiro SD. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science 1997 277: 2002 4.
186. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999 274: 21491 4.
187. Pardo A, Selman M. Proteinase-antiproteinase imbalance in the pathogenesis of emphysema: the role of metalloproteinases in lung damage. Histol Histopathol 1999 14: 227 33.
188. Shapiro SD. The macrophage in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999 160: S29 32.
189. Russell RE, Thorley A, Culpitt SV et al. Alveolar macrophage-mediated elastolysis: roles of matrix metalloproteinases, cysteine, and serine proteases. Am J Physiol Lung Cell Mol Physiol 2002 283: L867 73.
190. Russell RE, Culpitt SV, DeMatos C et al. Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2002 26: 602 9.
191. Lucey EC, Keane J, Kuang PP, Snider GL, Goldstein RH. Severity of elastase-induced emphysema is decreased in tumor necrosis factor-alpha and interleukin-1beta receptor-deficient mice. Lab Invest 2002 82: 79 85.
192. Eriksson S. Studies in alpha 1-antitrypsin deficiency. Acta Med Scand Suppl 1965 432: 1 85.
193. Du Bois RM, Bernaudin JF, Paakko P et al. Human neutrophils express the alpha 1-antitrypsin gene and produce alpha 1-antitrypsin. Blood 1991 77: 2724 30.
194. Mornex JF, Chytil-Weir A, Martinet Y, Courtney M, LeCocq JP, Crystal RG. Expression of the alpha-1-antitrypsin gene in mononuclear phagocytes of normal and alpha-1-antitrypsin-deficient individuals. J Clin Invest 1986 77: 1952 61.
195. Travis J, Salvesen GS. Human plasma proteinase inhibitors. Annu Rev Biochem 1983 52: 655 709.
196. Thompson RC, Ohlsson K. Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. Proc Natl Acad Sci U S A 1986 83: 6692 6.
197. Hiemstra PS, Maassen RJ, Stolk J, Heinzel-Wieland R, Steffens GJ, Dijkman JH. Antibacterial activity of antileukoprotease. Infect Immun 1996 64: 4520 4.
198. Ying QL, Simon SR. Kinetics of the inhibition of human leukocyte elastase by elafin, a 6-kilodalton elastase-specific inhibitor from human skin. Biochemistry 1993 32: 1866 74.
199. Ying QL, Simon SR. Kinetics of the inhibition of proteinase 3 by elafin. Am J Respir Cell Mol Biol 2001 24: 83 9.
200. Thurlbeck WM, Angus GE, Pare JP. Mucous gland hypertrophy in chronic bronchitis, and its occurrence in smokers. Br J Dis Chest 1963 57: 73 8.
201. de Bentzmann S, Polette M, Zahm JM et al. Pseudomonas aeruginosa virulence factors delay airway epithelial wound repair by altering the actin cytoskeleton and inducing overactivation of epithelial matrix metalloproteinase-2. Lab Invest 2000 80: 209 19.
202. Zahm JM, Chevillard M, Puchelle E. Wound repair of human surface respiratory epithelium. Am J Respir Cell Mol Biol 1991 5: 242 8.
203. Lechapt-Zalcman E, Pruliere-Escabasse V, Advenier D et al. Transforming growth factor-beta1 increases airway wound repair via MMP-2 upregulation: a new pathway for epithelial wound repair? Am J Physiol Lung Cell Mol Physiol 2006 290: L1277 82.
204. Hogg JC, Chu F, Utokaparch S et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004 350: 2645 53.
205. Kapanci Y, Burgan S, Pietra GG, Conne B, Gabbiani G. Modulation of actin isoform expression in alveolar myofibroblasts (contractile interstitial cells) during pulmonary hypertension. Am J Pathol 1990 136: 881 9.
206. Behzad AR, Chu F, Walker DC. Fibroblasts are in a position to provide directional information to migrating neutrophils during pneumonia in rabbit lungs. Microvasc Res 1996 51: 303 16.
207. Burns AR, Smith CW, Walker DC. Unique structural features that influence neutrophil emigration into the lung. Physiol Rev 2003 83: 309 36.
208. Sirianni FE, Chu FS, Walker DC. Human alveolar wall fibroblasts directly link epithelial type 2 cells to capillary endothelium. Am J Respir Crit Care Med 2003 168: 1532 7.
209. Pang G, Couch L, Batey R, Clancy R, Cripps A. GM-CSF, IL-1 alpha, IL-1 beta, IL-6, IL-8, IL-10, ICAM-1 and VCAM-1 gene expression and cytokine production in human duodenal fibroblasts stimulated with lipopolysaccharide, IL-1 alpha and TNF-alpha. Clin Exp Immunol 1994 96: 437 43.
210. Racine-Samson L, Rockey DC, Bissell DM. The role of alpha1beta1 integrin in wound contraction. A quantitative analysis of liver myofibroblasts in vivo and in primary culture. J Biol Chem 1997 272: 30911 7.
211. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994 331: 1286 92.
212. Kovacs EJ, DiPietro LA. Fibrogenic cytokines and connective tissue production. FASEB J 1994 8: 854 61.
213. Synenki L, Chandel NS, Budinger GR et al. Bronchoalveolar lavage fluid from patients with acute lung injury/acute respiratory distress syndrome induces myofibroblast differentiation. Crit Care Med 2007 35: 842 8.
214. Ihn H. Pathogenesis of fibrosis: role of TGF-beta and CTGF. Curr Opin Rheumatol 2002 14: 681 5.
215. Xie S, Sukkar MB, Issa R, Oltmanns U, Nicholson AG, Chung KF. Regulation of TGF-beta 1-induced connective tissue growth factor expression in airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2005 288: L68 76.
216. Toossi Z, Hirsch CS, Hamilton BD, Knuth CK, Friedlander MA, Rich EA. Decreased production of TGF-beta 1 by human alveolar macrophages compared with blood monocytes. J Immunol 1996 156: 3461 8.
217. Jeffery PK. Differences and similarities between chronic obstructive pulmonary disease and asthma. Clin Exp Allergy 1999 29 (Suppl. 2 14 26.
218. Jeffery PK. Remodeling and inflammation of bronchi in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 2004 1: 176 83.
219. Casalino-Matsuda SM, Monzon ME, Forteza RM. Epidermal growth factor receptor activation by epidermal growth factor mediates oxidant-induced goblet cell metaplasia in human airway epithelium. Am J Respir Cell Mol Biol 2006 34: 581 91.
220. Danahay H, Atherton H, Jones G, Bridges RJ, Poll CT. Interleukin-13 induces a hypersecretory ion transport phenotype in human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol 2002 282: L226 36.
221. Grunig G, Warnock M, Wakil AE et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 1998 282: 2261 3.
222. Zhu Z, Homer RJ, Wang Z et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 1999 103: 779 88.
223. Atherton HC, Jones G, Danahay H. IL-13-induced changes in the goblet cell density of human bronchial epithelial cell cultures: MAP kinase and phosphatidylinositol 3-kinase regulation. Am J Physiol Lung Cell Mol Physiol 2003 285: L730 9.
224. Barcelo B, Pons J, Fuster A et al. Intracellular cytokine profile of T lymphocytes in patients with chronic obstructive pulmonary disease. Clin Exp Immunol 2006 145: 474 9.
225. Sahlander K, Palmberg L, Larsson B. Altered expression of inflammatory markers in blood in pig farmers. Eur Respir J 2005 26 (Suppl. 49 584s.
226. Mastrangelo G, Tartari M, Fedeli U, Fadda E, Saia B. Ascertaining the risk of chronic obstructive pulmonary disease in relation to occupation using a case-control design. Occup Med (Lond) 2003 53: 165 72.
227. Monso E, Riu E, Radon K et al. Chronic obstructive pulmonary disease in never-smoking animal farmers working inside confinement buildings. Am J Ind Med 2004 46: 357 62.
228. Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med 2006 12: 99 106.
229. Boutten A, Bonay M, Laribe S et al. Decreased expression of interleukin 13 in human lung emphysema. Thorax 2004 59: 850 4.
230. Raaberg L, Nexo E, Buckley S, Luo W, Snead ML, Warburton D. Epidermal growth factor transcription, translation, and signal transduction by rat type II pneumocytes in culture. Am J Respir Cell Mol Biol 1992 6: 44 9.
231. Sanchez-Esteban J, Wang Y, Gruppuso PA, Rubin LP. Mechanical stretch induces fetal type II cell differentiation via an epidermal growth factor receptor-extracellular-regulated protein kinase signaling pathway. Am J Respir Cell Mol Biol 2004 30: 76 83.
232. Aarbiou J, Verhoosel RM, Van Wetering S et al. Neutrophil defensins enhance lung epithelial wound closure and mucin gene expression in vitro. Am J Respir Cell Mol Biol 2004 30: 193 201.
233. Shaykhiev R, Beisswenger C, Kandler K et al. Human endogenous antibiotic LL-37 stimulates airway epithelial cell proliferation and wound closure. Am J Physiol Lung Cell Mol Physiol 2005 289: L842 8.
234. Sanghavi JN, Rabe KF, Kim JS, Magnussen H, Leff AR, White SR. Migration of human and guinea pig airway epithelial cells in response to calcitonin gene-related peptide. Am J Respir Cell Mol Biol 1994 11: 181 7.
235. Zahm JM, Debordeaux C, Raby B, Klossek JM, Bonnet N, Puchelle E. Motogenic effect of recombinant HGF on airway epithelial cells during the in vitro wound repair of the respiratory epithelium. J Cell Physiol 2000 185: 447 53.
236. Kim JS, McKinnis VS, White SR. Migration of guinea pig airway epithelial cells in response to bombesin analogues. Am J Respir Cell Mol Biol 1997 16: 259 66.
237. Kasahara Y, Tuder RM, Cool CD, Lynch DA, Flores SC, Voelkel NF. Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. Am J Respir Crit Care Med 2001 163: 737 44.
238. Yokohori N, Aoshiba K, Nagai A. Increased levels of cell death and proliferation in alveolar wall cells in patients with pulmonary emphysema. Chest 2004 125: 626 32.
239. Hodge S, Hodge G, Holmes M, Reynolds PN. Increased airway epithelial and T-cell apoptosis in COPD remains despite smoking cessation. Eur Respir J 2005 25: 447 54.
240. Gerber HP, McMurtrey A, Kowalski J et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998 273: 30336 43.
241. Tuder RM, Flook BE, Voelkel NF. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. J Clin Invest 1995 95: 1798 807.
242. Kasahara Y, Tuder RM, Taraseviciene-Stewart L et al. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest 2000 106: 1311 9.
243. Kanazawa H, Asai K, Hirata K, Yoshikawa J. Possible effects of vascular endothelial growth factor in the pathogenesis of chronic obstructive pulmonary disease. Am J Med 2003 114: 354 8.
244. Tomita K, Caramori G, Lim S et al. Increased p21(CIP1/WAF1) and B cell lymphoma leukemia-x(L) expression and reduced apoptosis in alveolar macrophages from smokers. Am J Respir Crit Care Med 2002 166: 724 31.
245. Brodbeck WG, Shive MS, Colton E, Ziats NP, Anderson JM. Interleukin-4 inhibits tumor necrosis factor-alpha-induced and spontaneous apoptosis of biomaterial-adherent macrophages. J Lab Clin Med 2002 139: 90 100.
246. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004 59: 574 80.
247. Dentener MA, Creutzberg EC, Schols AM et al. Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations. Thorax 2001 56: 721 6.
248. Eid AA, Ionescu AA, Nixon LS et al. Inflammatory response and body composition in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001 164: 1414 8.
249. Mannino DM, Ford ES, Redd SC. Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination. Am J Med 2003 114: 758 62.
250. Mendall MA, Strachan DP, Butland BK et al. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J 2000 21: 1584 90.
251. Yasuda N, Gotoh K, Minatoguchi S et al. An increase of soluble Fas, an inhibitor of apoptosis, associated with progression of COPD. Respir Med 1998 92: 993 9.
252. Alessandri C, Basili S, Violi F, Ferroni P, Gazzaniga PP, Cordova C. Hypercoagulability state in patients with chronic obstructive pulmonary disease. Chronic Obstructive Bronchitis and Haemostasis Group. Thromb Haemost 1994 72: 343 6.
253. Dahl M, Tybjaerg-Hansen A, Vestbo J, Lange P, Nordestgaard BG. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001 164: 1008 11.
254. Engstrom G, Lind P, Hedblad B et al. Lung function and cardiovascular risk: relationship with inflammation-sensitive plasma proteins. Circulation 2002 106: 2555 60.
255. James AL, Knuiman MW, Divitini ML, Musk AW, Ryan G, Bartholomew HC. Associations between white blood cell count, lung function, respiratory illness and mortality: the Busselton Health Study. Eur Respir J 1999 13: 1115 9.
256. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease Circulation 2003 107: 1514 9.
257. Sin DD, Man SF. Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the dose matter? Eur Respir J 2003 21: 260 6.
258. Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001 164: 580 4.
259. Sin DD, Wu L, Anderson JA et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005 60: 992 7.
260. Soriano JB, Vestbo J, Pride NB, Kiri V, Maden C, Maier WC. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J 2002 20: 819 25.
261. Calverley PM, Anderson JA, Celli B et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007 356: 775 89.
262. Sin DD, Lacy P, York E, Man SF. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004 170: 760 5.
263. Huiart L, Ernst P, Ranouil X, Suissa S. Low-dose inhaled corticosteroids and the risk of acute myocardial infarction in COPD. Eur Respir J 2005 25: 634 9.
264. De Godoy I, Donahoe M, Calhoun WJ, Mancino J, Rogers RM. Elevated TNF-alpha production by peripheral blood monocytes of weight-losing COPD patients. Am J Respir Crit Care Med 1996 153: 633 7.
265. Di Francia M, Barbier D, Mege JL, Orehek J. Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1994 150: 1453 5.
266. Takabatake N, Nakamura H, Abe S et al. The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000 161: 1179 84.
267. Opazo Saez AM, Seow CY, Pare PD. Peripheral airway smooth muscle mechanics in obstructive airways disease. Am J Respir Crit Care Med 2000 161: 910 7.
268. Deshpande DA, Walseth TF, Panettieri RA, Kannan MS. CD38/cyclic ADP-ribose-mediated Ca2+ signaling contributes to airway smooth muscle hyper-responsiveness. FASEB J 2003 17: 452 4.
269. Tliba O, Panettieri RA Jr., Tliba S, Walseth TF, Amrani Y. Tumor necrosis factor-alpha differentially regulates the expression of proinflammatory genes in human airway smooth muscle cells by activation of interferon-beta-dependent CD38 pathway. Mol Pharmacol 2004 66: 322 9.
270. Deshpande DA, Dogan S, Walseth TF et al. Modulation of calcium signaling by interleukin-13 in human airway smooth muscle: role of CD38/cyclic adenosine diphosphate ribose pathway. Am J Respir Cell Mol Biol 2004 31: 36 42.
271. Tliba O, Cidlowski JA, Amrani Y. CD38 expression is insensitive to steroid action in cells treated with tumor necrosis factor-alpha and interferon-gamma by a mechanism involving the up-regulation of the glucocorticoid receptor beta isoform. Mol Pharmacol 2006 69: 588 96.
272. Lammers JW, Minette P, McCusker M, Barnes PJ. The role of pirenzepine-sensitive (M1) muscarinic receptors in vagally mediated bronchoconstriction in humans. Am Rev Respir Dis 1989 139: 446 9.
273. Ramnarine SI, Haddad EB, Khawaja AM, Mak JC, Rogers DF. On muscarinic control of neurogenic mucus secretion in ferret trachea. J Physiol 1996 2: 577 86.
274. Ishihara H, Shimura S, Satoh M et al. Muscarinic receptor subtypes in feline tracheal submucosal gland secretion. Am J Physiol 1992 262: L223 8.
275. Mak JC, Barnes PJ. Autoradiographic visualization of muscarinic receptor subtypes in human and guinea pig lung. Am Rev Respir Dis 1990 141: 1559 68.
276. Minette PA, Barnes PJ. Prejunctional inhibitory muscarinic receptors on cholinergic nerves in human and guinea pig airways. J Appl Physiol 1988 64: 2532 7.
277. On LS, Boonyongsunchai P, Webb S, Davies L, Calverley PM, Costello RW. Function of pulmonary neuronal M(2) muscarinic receptors in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001 163: 1320 5.
278. Minette PA, Lammers JW, Dixon CM, McCusker MT, Barnes PJ. A muscarinic agonist inhibits reflex bronchoconstriction in normal but not in asthmatic subjects. J Appl Physiol 1989 67: 2461 5.
279. Gosens R, Bromhaar MM, Tonkes A et al. Muscarinic M(3) receptor-dependent regulation of airway smooth muscle contractile phenotype. Br J Pharmacol 2004 141: 943 50.
280. Roffel AF, Elzinga CR, Van Amsterdam RG, De Zeeuw RA, Zaagsma J. Muscarinic M2 receptors in bovine tracheal smooth muscle: discrepancies between binding and function. Eur J Pharmacol 1988 153: 73 82.
281. Tokuyama K, Kuo HP, Rohde JA, Barnes PJ, Rogers DF. Neural control of goblet cell secretion in guinea pig airways. Am J Physiol 1990 259: L108 15.
282. Klapproth H, Reinheimer T, Metzen J et al. Non-neuronal acetylcholine, a signalling molecule synthesized by surface cells of rat and man. Naunyn Schmiedebergs Arch Pharmacol 1997 355: 515 23.
283. Wessler I, Kirkpatrick CJ, Racke K. The cholinergic 'pitfall': acetylcholine, a universal cell molecule in biological systems, including humans. Clin Exp Pharmacol Physiol 1999 26: 198 205.
284. Krause RM, Hamann M, Bader CR, Liu JH, Baroffio A, Bernheim L. Activation of nicotinic acetylcholine receptors increases the rate of fusion of cultured human myoblasts. J Physiol 1995 3: 779 90.
285. Fujii T, Tsuchiya T, Yamada S et al. Localization and synthesis of acetylcholine in human leukemic T cell lines. J Neurosci Res 1996 44: 66 72.
286. Fujii T, Yamada S, Watanabe Y et al. Induction of choline acetyltransferase mRNA in human mononuclear leukocytes stimulated by phytohemagglutinin, a T-cell activator. J Neuroimmunol 1998 82: 101 7.
287. Kawashima K, Fujii T, Watanabe Y, Misawa H. Acetylcholine synthesis and muscarinic receptor subtype mRNA expression in T-lymphocytes. Life Sci 1998 62: 1701 5.
288. Fujii T, Kawashima K. Calcium signaling and c-Fos gene expression via M3 muscarinic acetylcholine receptors in human T- and B-cells. Jpn J Pharmacol 2000 84: 124 32.
289. Fujii T, Kawashima K. An independent non-neuronal cholinergic system in lymphocytes. Jpn J Pharmacol 2001 85: 11 5.
290. Hagforsen E, Einarsson A, Aronsson F, Nordlind K, Michaelsson G. The distribution of choline acetyltransferase- and acetylcholinesterase-like immunoreactivity in the palmar skin of patients with palmoplantar pustulosis. Br J Dermatol 2000 142: 234 42.
291. Kanefsky J, Lenburg M, Hai CM. Cholinergic receptor and cyclic stretch-mediated inflammatory gene expression in intact ASM. Am J Respir Cell Mol Biol 2006 34: 417 25.
292. Koyama S, Rennard SI, Robbins RA. Acetylcholine stimulates bronchial epithelial cells to release neutrophil and monocyte chemotactic activity. Am J Physiol 1992 262: L466 71.
293. Koyama S, Sato E, Nomura H, Kubo K, Nagai S, Izumi T. Acetylcholine and substance P stimulate bronchial epithelial cells to release eosinophil chemotactic activity. J Appl Physiol 1998 84: 1528 34.
294. Profita M, Giorgi RD, Sala A et al. Muscarinic receptors, leukotriene B4 production and neutrophilic inflammation in COPD patients. Allergy 2005 60: 1361 9.
295. Proskocil BJ, Sekhon HS, Jia Y et al. Acetylcholine is an autocrine or paracrine hormone synthesized and secreted by airway bronchial epithelial cells. Endocrinology 2004 145: 2498 506.
296. Reinheimer T, Baumgartner D, Hohle KD, Racke K, Wessler I. Acetylcholine via muscarinic receptors inhibits histamine release from human isolated bronchi. Am J Respir Crit Care Med 1997 156: 389 95.
297. Reinheimer T, Mohlig T, Zimmermann S, Hohle KD, Wessler I. Muscarinic control of histamine release from airways. Inhibitory M1-receptors in human bronchi but absence in rat trachea. Am J Respir Crit Care Med 2000 162: 534 8.
298. Strom TB, Deisseroth A, Morganroth J, Carpenter CB, Merrill JP. Alteration of the cytotoxic action of sensitized lymphocytes by cholinergic agents and activators of adenylate cyclase. Proc Natl Acad Sci U S A 1972 69: 2995 9.
299. Krymskaya VP, Orsini MJ, Eszterhas AJ et al. Mechanisms of proliferation synergy by receptor tyrosine kinase and G protein-coupled receptor activation in human airway smooth muscle. Am J Respir Cell Mol Biol 2000 23: 546 54.
300. Gosens R, Nelemans SA, Grootte Bromhaar MM, McKay S, Zaagsma J, Meurs H. Muscarinic M3-receptors mediate cholinergic synergism of mitogenesis in airway smooth muscle. Am J Respir Cell Mol Biol 2003 28: 257 62.
301. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003 58: 399 404.
302. Donohue JF, van JA, Bateman ED et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002 122: 47 55.
303. van Noord JA, Aumann JL, Janssens E et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005 26: 214 22.
304. Dusser D, Bravo ML, Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J 2006 27: 547 55.
305. Niewoehner DE, Rice K, Cote C et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005 143: 317 26.
306. Gosens R, Bos IS, Zaagsma J, Meurs H. Protective effects of tiotropium bromide in the progression of airway smooth muscle remodeling. Am J Respir Crit Care Med 2005 171: 1096 102.
307. Calverley P, Pauwels R, Vestbo J et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003 361: 449 56.
308. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003 22: 912 9.
309. Szafranski W, Cukier A, Ramirez A et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003 21: 74 81.
310. Boman G, Backer U, Larsson S, Melander B, Wahlander L. Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases. Eur J Respir Dis 1983 64: 405 15.
311. Poole PJ, Black PN. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. BMJ 2001 322: 1271 4.
312. Decramer M, Rutten-van Molken M, Dekhuijzen PN et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005 365: 1552 60.
313. Jorenby DE, Leischow SJ, Nides MA et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999 340: 685 91.
314. Tashkin D, Kanner R, Bailey W et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 2001 357: 1571 5.
315. Jorenby DE, Hays JT, Rigotti NA et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006 296: 56 63.
316. Tonstad S, Tonnesen P, Hajek P, Williams KE, Billing CB, Reeves KR. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006 296: 64 71.
317. White JR, Lee JM, Young PR et al. Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J Biol Chem 1998 273: 10095 8.
318. Evans DJ, Barnes PJ, Spaethe SM, Van Alstyne EL, Mitchell MI, O'Connor BJ. Effect of a leukotriene B4 receptor antagonist, LY293111, on allergen induced responses in asthma. Thorax 1996 51: 1178 84.
319. Marc MM, Korosec P, Kosnik M et al. Complement factors c3a, c4a, and c5a in chronic obstructive pulmonary disease and asthma. Am J Respir Cell Mol Biol 2004 31: 216 9.
320. Aldonyte R, Jansson L, Piitulainen E, Janciauskiene S. Circulating monocytes from healthy individuals and COPD patients. Respir Res 2003 4: 11.
321. Fuke S, Betsuyaku T, Nasuhara Y, Morikawa T, Katoh H, Nishimura M. Chemokines in bronchiolar epithelium in the development of chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2004 31: 405 12.
322. De Boer WI. Cytokines and therapy in COPD: a promising combination? Chest 2002 121: 209S 18S.
323. Kogan TP, Dupre B, Bui H et al. Novel synthetic inhibitors of selectin-mediated cell adhesion: synthesis of 1,6-bis [3-(3-carboxymethylphenyl) -4-(2-alpha-d-mannopyranosyloxy) phnyl]hexane (TBC1269). J Med Chem 1998 41: 1099 111.
324. Rennard SI, Fogarty C, Kelsen S et al. The safety and efficacy of infliximab in moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007 175: 926 34.
325. van der Vaart H, Koeter GH, Postma DS, Kauffman HF, Ten Hacken NH. First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005 172: 465 9.
326. Masuyama H, Hiramatsu Y, Kudo T. Effect of retinoids on fetal lung development in the rat. Biol Neonate 1995 67: 264 73.
327. Mollard R, Ghyselinck NB, Wendling O, Chambon P, Mark M. Stage-dependent responses of the developing lung to retinoic acid signaling. Int J Dev Biol 2000 44: 457 62.
328. Lin BC, Hong SH, Krig S, Yoh SM, Privalsky ML. A conformational switch in nuclear hormone receptors is involved in coupling hormone binding to corepressor release. Mol Cell Biol 1997 17: 6131 8.
329. Massaro GD, Massaro D. Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats. Nat Med 1997 3: 675 7.
330. Tepper J, Pfeiffer J, Aldrich M et al. Can retinoic acid ameliorate the physiologic and morphologic effects of elastase instillation in the rat? Chest 2000 117: 242S 4S.
331. Mao JT, Tashkin DP, Belloni PN, Baileyhealy I, Baratelli F, Roth MD. All-trans retinoic acid modulates the balance of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in patients with emphysema. Chest 2003 124: 1724 32.